Otsuka Pharmaceutical

Total: $62.7 million

Top drug
Abilify: $62.4 million
Watch the TV commercial here >>

Japanese drugmaker Otsuka puts all of its advertising eggs into one product basket, and to good effect. Its atypical antipsychotic Abilify is well-recognized and a blockbuster. The drug is Otsuka's top product and brought in $4.2 billion last year, but it loses exclusivity in 2015. The company recently won FDA approval for a long-acting, once-per-month injectable version of the drug, but it's searching around for products to fill in behind Abilify. The drugmaker may have something new to advertise next year. It recently made an $886 million offer for Astex Pharmaceuticals ($ASTX), which specializes in cancer drugs. The California-based company developed a leukemia drug--Dacogen, marketed by Eisai and Johnson & Johnson's ($JNJ) Janssen unit--but its pipeline is what provides the greatest potential upside.

Otsuka Pharmaceutical

Suggested Articles

Several of the industry's top players had a strong performance in the fourth quarter, growing revenues at high single digits. Others? Not so much.

Viatris, the merger of Mylan and Pfizer's Upjohn, has fleshed out its board and C-suite with a raft of Pfizer and Mylan veterans.

An FDA approval of Lilly’s Cyramza combo would pit it against AZ's Tagrisso, which has charted impressive survival gains in EGFR-positive lung cancer.